We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+31.1%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$901M
AUM Growth
+$18M
Cap. Flow
-$112M
Cap. Flow %
-12.47%
Top 10 Hldgs %
81.99%
Holding
29
New
3
Increased
5
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$10.6M
2
DBVT
DBV Technologies
DBVT
+$8.84M
3
MDCO
Medicines Co
MDCO
+$5.65M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$5.29M
5
AMRN
Amarin Corp
AMRN
+$4.91M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$49.6M
2
VKTX icon
Viking Therapeutics
VKTX
+$35.6M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26.6M
4
MGNX icon
MacroGenics
MGNX
+$25.7M
5
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
26
MacroGenics
MGNX
$235M
– –
-1,245,000
Closed -$25.7M
SRPT icon
27
Sarepta Therapeutics
SRPT
$1.57B
– –
-375,000
Closed -$49.6M
VKTX icon
28
Viking Therapeutics
VKTX
$3.7B
– –
-3,750,000
Closed -$35.6M
ONCT
29
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-9,357
Closed -$20.1M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Boxer Capital held 29 positions worth $901M, up 2% from $883M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Boxer Capital withdrew a net $112M in Q3 2018, closing 5 positions and reducing 1 holding. Its most notable exit was Sarepta Therapeutics, an estimated $49.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Amarin Corp worth $21.2M.

  • Boxer Capital's largest Q3 2018 buy was Amarin Corp: 65,000 shares worth $21.2M.
  • Boxer Capital added most to PTC Therapeutics in Q3 2018, an estimated $10.6M increase.
  • Boxer Capital's biggest Q3 2018 reduction was Bellerophon Therapeutics, Inc., cutting an estimated $594K.
  • Boxer Capital fully exited Sarepta Therapeutics in Q3 2018, selling an estimated $49.6M.
  • Boxer Capital's ten largest holdings make up 82% of its $901M portfolio in Q3 2018.
  • Boxer Capital opened 3 new positions and closed 5 in Q3 2018.
  • Boxer Capital's portfolio value rose 2% quarter-over-quarter to $901M.

Based on Boxer Capital's 13F filing for Q3 2018, filed 14 Nov 2018.